1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow Adrenal Cortex Diseases: new trials by email Literature Review of Adrenal Cortex Diseases trials Research Report on Adrenal Cortex Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 |
Adrenal Cortex Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Medullary (1) · Carcinoma, Merkel Cell (1) · Glucagonoma (1) · Insulinoma (1) · Multiple Endocrine Neoplasia Type 1 (1) · Multiple Endocrine Neoplasia Type 2a (1) · Multiple Endocrine Neoplasia Type 2b (1) · Neuroendocrine Tumors (1) · Non functioning pancreatic endocrine tumor (1) · Pheochromocytoma (1) · Somatostatinoma (1) · Vipoma (1) · Zollinger-Ellison Syndrome (1)
Adenocarcinoma (1) · Adenoma (1) · Adenoma, Islet Cell (1) · Adrenal Gland Diseases (1) · Adrenal Gland Neoplasms (1) · Carcinoma (1) · Carcinoma, Islet Cell (1) · Carcinoma, Neuroendocrine (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Virus Infections (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Duodenal Diseases (1) · Endocrine Gland Neoplasms (1)
Capecitabine (1) · Temozolomide (1) · veliparib (1)
Vanderbilt-Ingram Cancer Center (1)